Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Debt (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Non-Current Debt for 5 consecutive years, with $163.7 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Debt fell 19.47% year-over-year to $163.7 million; the TTM value through Mar 2026 reached $163.7 million, down 19.47%, while the annual FY2025 figure was $209.1 million, 3.81% up from the prior year.
  • Non-Current Debt hit $163.7 million in Q1 2026 for Phathom Pharmaceuticals, down from $209.1 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $209.1 million in Q4 2025 and bottomed at $91.0 million in Q1 2022.
  • Average Non-Current Debt over 5 years is $146.6 million, with a median of $149.0 million recorded in 2024.
  • Year-over-year, Non-Current Debt soared 78.34% in 2024 and then fell 19.47% in 2026.
  • Phathom Pharmaceuticals' Non-Current Debt stood at $95.3 million in 2022, then soared by 44.69% to $137.8 million in 2023, then surged by 46.12% to $201.4 million in 2024, then increased by 3.81% to $209.1 million in 2025, then decreased by 21.72% to $163.7 million in 2026.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $163.7 million, $209.1 million, and $207.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.